Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01103505 · ClinicalTrials.gov registry record · NA
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
A NA study, sponsored by Notal Vision.
- Completed
- Registry status
- NA
- Development phase
- 1,520
- Enrollment target
NCT01103505: Completed NA study, sponsored by Notal Vision.
NCT01103505 is a NA study that has completed, run by Notal Vision. The registered enrollment target is 1,520 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01103505, a NA study, has completed, sponsored by Notal Vision.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,520 participants
- Enrollment target
Study Summary
The overall objective of this two arm randomized clinical trial (RCT) is to determine if home monitoring using the comprehensive visual field and telemedicine solution based on the ForeseeHome device in AREDS2 improves detection of progression to choroidal neovascularization (CNV) when compared with standard care.
Primary Outcome
Mean change in BCVA (logMAR letters) from baseline to the time of confirmed progression to CNV in the ForeseeHome device monitoring group compared to the standard care group.
Interventions
- DIAGNOSTIC_TEST ForeseeHome AMD Monitoring Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,520 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-12 |
| Phase | NA |
What the finished NCT01103505 record still lists
NCT01103505 is an interventional study that assigns participants to a tested intervention. Its 1,520 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which ForeseeHome AMD Monitoring Device is the first listed.
NCT01103505 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01103505 about?
NCT01103505 is a clinical study titled "HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device". The overall objective of this two arm randomized clinical trial (RCT) is to determine if home monitoring using the comprehensive visual field and telemedicine solution based on the ForeseeHome device in AREDS2 improves detection of progression to choroidal neovascularization (CNV) when compared with...
What is the current status of trial NCT01103505?
This trial is currently completed. It is a NA study. The enrollment target is 1,520 participants. The study started on 2010-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01103505?
The interventions under investigation include: ForeseeHome AMD Monitoring Device (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT01103505?
This trial is sponsored by Notal Vision, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01103505's enrollment target sits among peer trials
1,520 65th of 2000 higher than 1,936 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07232017 · 1,520 participants
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
- NCT06876714 · 1,524 participants · Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- NCT06257082 · 1,526 participants · NA
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia